SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Roche's tower in Shanghai, China
Tariffs
Roche in ‘Very, Very Good Position’ To Weather Trump Tariffs but M&A May Suffer
Roche’s exposure to the tariffs is mostly limited to four medicines, three of which it already produces in the U.S., according to CEO Thomas Schinecker, who declined to reveal what these assets are.
April 24, 2025
 · 
2 min read
 · 
Tristan Manalac
Sponsored
Steminent Stands Ready to Showcase Novel MSC-based Therapy for Spinocerebellar Ataxia at Global Stage
Founded in 2007, Steminent Biotherapeutics specializes in developing innovative stem cell-based therapeutics that offer new hope for patients with rare neurodegenerative diseases
April 24, 2025
 · 
6 min read
IN PARTNERSHIP WITH DIA
Webinar: AI, Regulation and the Law: Shaping the Future of Drug Development
In this discussion, our guests explore how recent regulatory changes are shaping the future of AI in drug development in the US market. Watch now.
April 23, 2025
 · 
1 min read
 · 
BioSpace Insights
New York City, New York United States - August 29 2021: NASDAQ, National Association of Securities Dealers Automated Quotations corporate logo sign near Times Square.
IPO
Swiss ADC Biotech Takes SPAC Track to NASDAQ
The deal is a blast from the not-too-distant past, when special purpose acquisition companies were an easy way for companies to list on the public market with a bundle of cash to operate on.
April 23, 2025
 · 
1 min read
 · 
Annalee Armstrong
Creative sketch collage of business people handshake gesture approval project development success colleagues cooperation support.
Deals
Genentech Offers up to $765M in Biobucks to Repertoire for I&I Drug Discovery
Roche’s Genentech is betting on the Flagship Pioneering–founded company’s discovery platform called DECODE to find new targets for an undisclosed autoimmune disorder.
April 23, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Background of scattered on a plain blue background of many tablets in the form of a silhouette of the continents of the world 3d illustration
Drug pricing
Trump Wants To Bring Back International Drug Pricing Policy: Reuters
The so-called ‘Most Favored Nations’ rule would set drug pricing for Medicare in line with the prices paid by other nations, where drugs can be much cheaper.
April 23, 2025
 · 
2 min read
 · 
Annalee Armstrong
Two boxing gloves give a fist bump on a colored background. Collage art
Lung cancer
Summit’s Bispecific Beats Yet Another Cancer Med, Pressuring Keytruda’s ‘Supremacy’
Analysts at BMO Capital Markets expect Summit and Akeso’s HARMONi-6 readout to put some pressure on Merck and its blockbuster biologic Keytruda.
April 23, 2025
 · 
2 min read
 · 
Tristan Manalac
Mentorship concept, guidance and leadership, empathy and communication, face to face heads, negotiation and persuasion, common ground, emotional intelligence, vector flat illustration
Career Advice
You’re Right, But No One’s Listening: 3 Steps To Make Your Voice Impossible To Ignore
Just raising the alarm won’t drive action. Use these three steps to turn insights into solutions that leadership can’t ignore.
April 23, 2025
 · 
4 min read
 · 
Angela Justice
Pictured: Bristol Myers Squibb office in California
Neuropsychiatric disorders
‘Strike 2?’ BMS Stumbles Again as Cobenfy Disappoints in Schizophrenia
Cobenfy’s late-stage flop is BMS’ second high-profile failure in as many weeks. The pharma announced last week that Camzyos was unable to improve disease burden in non-obstructive hypertrophic cardiomyopathy.
April 23, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS